CD123-CAR T cells(St Jude Children's Research Hospital)

N/A

Report date: 2023/06/07 20:00:31

Base Information

Drug NameCD123-CAR T cells(St Jude Children's Research Hospital)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD123
TargetsInterleukin-3 receptor subunit alpha
Therapy Area/IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmMyelodysplastic SyndromesPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesSt. Jude Children'S Research Hospital
China Registration ClassN/A

Develop Information

Active CompaniesSt. Jude Children'S Research Hospital
Inactive CompaniesN/A
Active IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmMyelodysplastic SyndromesPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A